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BENEFICIARIES’ OUT-OF-POCKET COSTS UNDER THE
MEDICARE PRESCRIPTION DRUG BENEFIT: EVIDENCE FROM
MEDICARE DISCOUNT DRUG CARD CLAIMS DATA
Esposito D1, Roebuck MC2, Lewis M2
1Mathematica Policy Research, Inc, Princeton, NJ, USA, 2Caremark,
Hunt Valley, MD, USA
OBJECTIVES: To investigate the potential impact of the stan-
dard Medicare prescription drug beneﬁt on beneﬁciaries who are
high utilizers and on beneﬁciaries who qualiﬁed for the Transi-
tional Assistance Program (TAP). METHODS: Simulation of
annual beneﬁciary out-of-pocket costs under the standard pre-
scription beneﬁt using Medicare discount card claims data for
37,425 enrolled beneﬁciaries (at least 6 months) who ﬁlled at
least one prescription between June 2004 and November 2005.
The results of this study should closely represent Medicare ben-
eﬁciaries’ drug using behavior as these data are more accurate
than self-reported or survey data. RESULTS: Annually, beneﬁ-
ciaries ﬁlled 19 prescriptions, on average, and had out-of-pocket
costs of $538. Average out-of-pocket costs among the top quar-
tile of utilizers (more than 26 ﬁlls annually) were $1155. Assum-
ing ﬁxed drug utilization patterns, simulated Part D costs
demonstrate that all beneﬁciaries would spend $412 out-of-
pocket (excluding premiums), on average, while high utilizers
would spend $779. Among high utilizers, 22% would have
greater than $2250 in total drug costs and fall into the beneﬁt’s
“doughnut hole.” TAP beneﬁciaries (46%) would have higher
out-of-pocket costs under Part D then under the drug card ($429
versus $256; p < 0.001), on average, because Medicare subsi-
dized their ﬁrst $600 in drug card ﬁlls annually. Under the drug
card, TAP beneﬁciaries ﬁlled more prescriptions (23 versus 15;
p < 0.001) and had lower out-of-pocket costs ($256 versus $781;
p < 0.001) annually than non-TAP beneﬁciaries. CONCLU-
SION: Out-of-pocket costs under Part D for TAP beneﬁciaries
and high utilizers (more than two prescriptions monthly) would
be more than $400 and $750, respectively. If TAP beneﬁciaries
do not qualify subsidized coverage under Part D and their drug
use remains ﬁxed, their out-of-pocket costs will increase. Bene-
ﬁciaries might reduce their utilization when faced with higher
out-of-pocket costs, with the potential for adverse impacts on
patients’ health.
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THE DECISION TO CONDUCT A HEAD-TO-HEAD
COMPARATIVE TRIAL: A GAME-THEORETIC ANALYSIS
Mansley EC1, Elbasha EH2,Teutsch SM1, Berger ML1
1Merck & Co., Inc, West Point, PA, USA, 2Merck & Co., Inc, Blue Bell,
PA, USA
OBJECTIVES: Recent Medicare legislation calls on AHRQ to
conduct research related to the comparative effectiveness of
health care items and services, including prescription drugs. This
reinforces earlier calls for “practical clinical trials” involving
clinically relevant treatment alternatives. We explored the 
decision of pharmaceutical companies to conduct such “head-to-
head” comparative trials. Our objectives were to: 1). better
understand the incentives and disincentives to conduct a com-
parative trial; 2). shed light on the hidden costs of a trial; 
3). characterize the conditions under which a trial will be 
undertaken; and 4). identify implications for public policy.
METHODS: In the context of a differentiated products oligop-
oly, we modeled a one-stage game involving two risk-neutral
pharmaceutical companies, each of which simultaneously
decides whether or not to conduct a head-to-head trial involv-
ing a direct comparison between its drug and that of the other
company. RESULTS: Our model suggests that an important
factor affecting a ﬁrm’s decision is the potential loss in market
share following a result of inferiority or comparability. This
“hidden cost” is higher for the Market Leader than the Market
Follower, making it less likely that the Leader will choose 
to conduct a trial. The model also suggests that in a full-
information environment it will never be the case that both ﬁrms
choose to conduct such a trial. Furthermore, if market shares
and the probability of proving superiority are similar for both
ﬁrms, it is quite possible that neither ﬁrm will choose to conduct
a trial. Finally, our results indicate that incentives that offset the
direct cost of a trial can prevent a “no-trial equilibrium”, even
when both ﬁrms face the possibility of an inferior outcome.
CONCLUSIONS: The generation of comparative information
through the conduct of clinical trials depends greatly on private
incentives, which may be subject to alteration through public
policy.
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BRITISH COLUMBIAN PHYSICIANS’ OPINIONS REGARDING
REFERENCE DRUG AND GENERIC SUBSTITUTION
PROGRAMS
Polinski J1, Maclure M2, Marshall B2, Cassels A2,Agnew-Blais J1,
Patrick A1, Schneeweiss S3
1Brigham and Women’s Hospital, Boston, MA, USA, 2University of
Victoria,Victoria, BC, Canada, 3Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA, USA
OBJECTIVE: To assess British Columbian (BC) physicians’ opin-
ions regarding reference drug programs (RDPs) and generic 
substitution programs (GSPs). METHODS: 208 telephone inter-
views on the economic and clinical appropriateness of RDPs and
GSPs were conducted with BC general practitioners. Responses
were rated on 5-point Likert scales: 1 = very inappropriate and
5 = very appropriate. Responses to questions on the economic
appropriateness were stratiﬁed by physicians’ understanding of
drug costs measured by estimating costs of a 30-day supply of
atorvastatin within ±$10 of the actual cost. RESULTS: Physi-
cians regarded both the clinical and economic appropriateness
of GSPs as greater than that of RDPs (p < 0.01). The rating of
clinical appropriateness of RDPs was signiﬁcantly correlated
with the rating of the therapeutic equivalence of ACE inhibitors
(p = 0.034) and calcium channel blockers (p = 0.019). This result
was independent of whether the RDP or a therapeutic equiva-
lence question was asked ﬁrst. Physicians signiﬁcantly underes-
timated the costs for a 30-day supply of two drugs: $28 (33%)
for omeprazole and $28 (34%) for atorvastatin. Physicians
whose cost estimates for atorvastatin were accurate were signif-
icantly less likely to consider RDPs (p = 0.003) and GSPs (p =
0.026) as economically appropriate than were those whose esti-
mates were inaccurate. CONCLUSIONS: BC physicians were
more comfortable with the clinical and economic appropriate-
ness of GSPs than with RDPs. While there is great agreement
between physicians’ opinions towards RDP and their assessment
of therapeutic equivalence within drug classes, similar agreement
does not exist between GSPs or RDPs and the accuracy of physi-
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cians’ cost estimates for commonly prescribed drugs. In fact,
physicians’ with inaccurate cost estimates were more likely to be
comfortable with both GSPs and RDPs. Physicians have explicit
opinions regarding the clinical and economic ramiﬁcations of
GSPs and RDPs, and these opinions should be considered in
planning and communicating drug policies.
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SUMMARY OF THE FIRST YEAR OF A DISEASE MANAGEMENT
PROGRAM IN PATIENTS WITH BLEEDING DISORDERS
Tencer T1, Shapiro A2, Roberson C2, Johnson KA1
1University of Southern California, Los Angeles, CA, USA, 2Indiana
Hemophilia and Thrombosis Center, Indianapolis, IN, USA
OBJECTIVE: To assess the cost and outcomes of a disease man-
agement program (DMP) for the bleeding disorder population
insured by a state insurance plan. METHODS: All bleeding dis-
order patients covered by the plan were enrolled into a DMP
administered by the Indiana Hemophilia & Thrombosis Center
(IHTC). A pre/post intervention study design was used, with a
prior year serving as the baseline period and 1-year post enroll-
ment as the study period. Claims data were used to assess hos-
pitalizations, ER visits, total medical costs and factor costs.
Medical records were used to assess disease severity and other
co-morbidities. T-tests and a regression analysis were used to
assess the impact of the DMP. RESULTS: Thirty continuously
enrolled patients had complete data. Due to the small sample size
and large variability in costs found in this population, none of
the analyses reached statistical signiﬁcance. Approximately 90%
of the population was male, 87% with hemophilia A. The
average cost of care in the baseline year and follow-up year were
$110,637 and $111,329 respectively (p = 0.99). Although factor
use increased by 29,625 units (p = 0.46), and accounted for
90.4% and 96.9% of costs, baseline versus ﬁrst year respectively,
the mean number of inpatient hospital days and ER visits
decreased from 1.36 and 1.6 to 0.43 (p = 0.12), and 0.43 (p =
0.23) respectively. The average total cost for patients who
switched to the DMP during the study period decreased from
$136,725 to $97,557 (p = 0.40) from baseline. CONCLUSION:
Although the DMP did not appear to statistically decrease total
costs, costs were contained even as factor utilization increased.
Additionally, there was a trend toward lower inpatient hospital
days and ER visits. Further enrollment may increase statistical
power and a longer study period will be used to completely assess
the impact of the DMP.
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CHARACTERISTICS OF SENIORS WITH HIGH ANNUAL
PRESCRIPTION DRUG EXPENDITURES: FINDINGS FROM THE
2002 AND 2003 MEDICAL EXPENDITURE PANEL SURVEY
Daniel GW, Malone DC
University of Arizona,Tucson, AZ, USA
OBJECTIVE: The Medicare Modernization Act of 2003 requires
drug plan sponsors to provide medication therapy management
(MTM) programs to beneﬁciaries with 1) annual drug expendi-
tures above $4000; 2) multiple comorbidities; and 3) multiple
prescription drugs. The purpose of this study was to obtain
nationally representative estimates of the proportion of seniors
who met the expenditure criteria and identify risk factors for
high annual drug expenditures. METHODS: Prescribed medi-
cines and demographic data came from the 2002 and 2003
Medical Expenditure Panel Survey (MEPS) for respondents ≥65
years of age. Survey-weighted logistic regression identiﬁed risk
factors for high drug expenditures. Candidate variables included
age, gender, race, income, education, marital status, functional
limitations, health status, presence of chronic conditions, body
mass index (BMI), and medical and prescription drug insurance.
Standard errors (SEs) were adjusted for complex survey design
and expenditures were adjusted to 2003 U.S. dollars. Annual
expenses of $3810 in 2003 were deemed equivalent to $4000 in
2005. RESULTS: An estimated 9.2% (SE ± 0.4%) of 36 million
seniors over 2002 and 2003 incurred more than $3810 annual
drug expenditures, accounting for 35% of $55.3 billion in drug
expenditures among all seniors. Respondents with high drug
expenditures reported 10.8 (±0.2) unique medications with
77.9% (±1.9%) reporting ≥8 medications; all had ≥3 medica-
tions. These respondents also had 5.2 (±0.1) chronic conditions;
60.5% (±2.3%) had ≥4 conditions. Diabetes, hyperlipidemia,
depression, and cardiac disease signiﬁcantly increased the risk of
high drug expenditures. Other signiﬁcant risk factors included
receiving help with activities of daily living (ADLs), housework
limitations, high BMI, fair/poor health, and total number of
chronic diseases. CONCLUSION: Respondents with drug
expenditures exceeding the MTM threshold obtain signiﬁcantly
more drugs and have a higher disease burden than those with
lower drug expenditures. Characteristics other than the number
and type of medications can be used to identify candidates for
MTM programs.
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PRESCRIPTION PATTERNS OF POTENTIALLY
INAPPROPRIATE MEDICATIONS AMONG OLDER MEDICARE
MANAGED CARE BENEFICIARIES
Bonnet PO,Yip JY, Leung M
SCAN, Long Beach, CA, USA
OBJECTIVES: This study examined the prevalence and patterns
of inappropriate medication use among older Medicare managed
care beneﬁciaries enrolled in a Southern California Social Health
Maintenance Organization. METHODS: The administrative
datasets used for the analysis contained demographics, enroll-
ment information, pharmacy claims, inpatient and outpatient
utilization for approximately 75,000 older Medicare beneﬁcia-
ries. The analytical sample included 47,978 members with con-
tinuous enrollment from July 1st 2004 to June 30th 2005. This
study was based on the inappropriate medication list developed
by Zhan (2001). The list was limited to medications that should
always be avoided or considered rarely appropriate regardless of
dose or diagnosis. Patients with at least one prescription claim
for an inappropriate medication were compared to patients
without. Different patterns of inappropriate medication use were
identiﬁed. Univariate and multivariate analyses were performed
to examine characteristics associated with these patterns.
RESULTS: 17.3% (8313/47,978) of the members ﬁlled at least
one claim for a potentially inappropriate medication. 51.2%
(4260/8313) of them ﬁlled multiple prescriptions for potentially
inappropriate medications. The average number of prescribing
providers was higher for members with inappropriate medica-
tions than for those without inappropriate medication claims
(3.84 vs. 2.69, p < 0.0001). Members with inappropriate med-
ication claims ﬁlled an average of 45 medications per year (vs.
32 for other members, p < 0.0001). Logistic regression showed
that inappropriate medication use was associated with younger
age (Odds ratio conﬁdence interval: 0.978–0.985), female gender
(CI:0.612–0.683), number of prescribing providers (CI:1.289–
1.320), and use of home and community-based services —HCBS-
(CI:1.281–1.434). Members who were younger (p = 0.0018),
female (p = 0.0030), dually eligible for Medicare and Medicaid
(p < 0.0001) and using HCBS (p < 0.0001) were more likely to
use multiple inappropriate medications. CONCLUSIONS:
The rate of inappropriate medication use was similar to rates
found in the literature but revealed the importance to develop
